News
Insights
Jobs
Career Advice
Companies
Hotbeds
More

SUBSCRIBE

SUBSCRIBE

News
Insights
Jobs
Career Advice
Companies
Hotbeds
More

Search Query

Search Results

Looking for jobs? Search jobs

6,751 Results

Type

Article (255)
Company Profile (3)
Press Release (6493)

Section

Business (1966)
Career Advice (2)
Deals (286)
Drug Development (1908)
Employer Resources (1)
FDA (63)
Job Trends (104)
News (3917)
Policy (166)

Tag

Date

Today (2)
Last 7 days (6)
Last 30 days (30)
Last 365 days (450)
2025 (59)
2024 (458)
2023 (615)
2022 (765)
2021 (718)
2020 (602)
2019 (409)
2018 (347)
2017 (412)
2016 (406)
2015 (401)
2014 (258)
2013 (163)
2012 (140)
2011 (170)
2010 (123)

Location

Africa (6)
Asia (413)
Australia (246)
California (71)
Canada (55)
China (2)
Colorado (13)
Europe (1247)
Florida (9)
Maryland (8)
Massachusetts (27)
Montana (8)
New Jersey (14)
New York (32)
North Carolina (11)
Northern California (11)
Ohio (2)
Pennsylvania (7)
South America (4)
Southern California (47)
Texas (4)

Filters

Type

Article (255)
Company Profile (3)
Press Release (6493)

Section

Business (1966)
Career Advice (2)
Deals (286)
Drug Development (1908)
Employer Resources (1)
FDA (63)
Job Trends (104)
News (3917)
Policy (166)

Tag

Date

Today (2)
Last 7 days (6)
Last 30 days (30)
Last 365 days (450)
2025 (59)
2024 (458)
2023 (615)
2022 (765)
2021 (718)
2020 (602)
2019 (409)
2018 (347)
2017 (412)
2016 (406)
2015 (401)
2014 (258)
2013 (163)
2012 (140)
2011 (170)
2010 (123)

Location

Africa (6)
Asia (413)
Australia (246)
California (71)
Canada (55)
China (2)
Colorado (13)
Europe (1247)
Florida (9)
Maryland (8)
Massachusetts (27)
Montana (8)
New Jersey (14)
New York (32)
North Carolina (11)
Northern California (11)
Ohio (2)
Pennsylvania (7)
South America (4)
Southern California (47)
Texas (4)

6,751 Results for "alladapt immunotherapeutics".

Sort By

FDA

Alladapt Immunotherapeutics Receives FDA Fast Track Designation for ADP101 for the Treatment of Mono- and Multi-Food Allergies

Alladapt Immunotherapeutics, today announced that ADP101, its investigational multi-food oral immunotherapy (mOIT) designed to simultaneously treat allergy to one or more of the world’s most significant food allergens, received Fast Track Designation from the U.S. Food and Drug Administration (FDA).

November 22, 2023
·
5 min read
Drug Development

Alladapt Immunotherapeutics Presents Phase 1/2 Harmony Data Demonstrating Therapeutic Potential and Safety of ADP101 for the Treatment of Food Allergy at 2023 ACAAI Annual Meeting

Alladapt Immunotherapeutics, Inc. announced that data from the Phase 1/2 Harmony study will be presented at the 2023 Annual Scientific Meeting of the American College of Asthma, Allergy and Immunology taking place Nov. 9-13.

November 9, 2023
·
7 min read
Drug Development

Alladapt Immunotherapeutics Announces Topline Pediatric Data from Phase 1/2 Harmony Study Evaluating ADP101 for the Treatment of Patients with Mono- and Multi-Food Allergy, as Presented at the EAACI Hybrid Congress

Alladapt Immunotherapeutics, Inc., a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address IgE-mediated food allergy, announced topline results from the Phase 1/2 Harmony study evaluating the efficacy and safety of ADP101 for the treatment of food allergy.

June 13, 2023
·
7 min read
Business

Alladapt Appoints Louise Peacock as Chief Regulatory Affairs and Quality Officer

Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address IgE-mediated food allergy, announced the appointment of Louise Peacock as Chief Regulatory Affairs and Quality Officer, effective May 1, 2023.

May 1, 2023
·
3 min read
Biotech Bay

Alladapt to Participate in Two Upcoming November 2022 Investor Conferences

Alladapt Immunotherapeutics Inc. announced that Ashley Dombkowski, Chief Executive Officer of Alladapt, will participate in two upcoming investor conferences in November.

November 8, 2022
·
2 min read
Biotech Bay

Alladapt to Present at the 41st Annual J.P. Morgan Healthcare Conference

Alladapt Immunotherapeutics Inc. today announced that Ashley Dombkowski, Chief Executive Officer of Alladapt, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 7:30 a.m. PT in San Francisco, CA.

January 4, 2023
·
1 min read
Press Releases

Paradox Immunotherapeutics Appoints Sandy Zweifach as Executive Chairman

January 7, 2025
·
3 min read
Press Releases

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

February 27, 2025
·
23 min read
Press Releases

Paradox Immunotherapeutics Secures $10 Million Investment from SymBiosis to Advance Therapies for Protein Misfolding Diseases

February 25, 2025
·
3 min read
Press Releases

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer

January 14, 2025
·
5 min read

1 of 676

BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.

Explore
About
More

© 1985 - 2025 BioSpace.com. All rights reserved.

twitter
instagram
facebook
linkedin